Monte Rosa Therapeutics, Inc. (GLUE) Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Monte Rosa Therapeutics, Inc. NASDAQ:GLUE Healthcare · Biotechnology
Mkt Cap $917.97M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Monte Rosa Therapeutics announced Novartis initiated a second Phase 2 study of the VAV1-directed molecular glue degrader MRT-6160 (DDY391), this one in active moderate to severe psoriatic arthritis.
The first patient visit triggers a $37.5 million milestone payment to Monte Rosa under the global exclusive license agreement, which carries up to $2.1 billion in total milestones.
Novartis funds and conducts Phase 2 development; Monte Rosa co-funds any Phase 3, shares 30% of U.S. profit/loss, and earns tiered ex-U.S. royalties, giving GLUE non-dilutive cash and validation of its partnered pipeline.
• 4d ago AI analysis › Press Release
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Therapeutics granted inducement equity awards to five newly hired non-executive employees under its 2026 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
The awards comprise options to purchase 86,725 shares at an $11.26 exercise price plus 19,150 restricted stock units, both with four-year vesting structures.
This is a routine hiring-related equity disclosure with no bearing on the company's clinical pipeline or financial position.
• 0mo ago AI analysis › Press Release ● Major ⚠ 2
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
Monte Rosa Therapeutics reported positive Phase 1 GFORCE-1 results for MRT-8102, a NEK7-directed molecular glue degrader, in 108 obese subjects with elevated cardiovascular risk.
NEK7 degradation was robust and sustained (~80-90% median) across all doses, with key ASCVD biomarkers (calprotectin -56%, SAA -51%, hsCRP -85%) normalized to healthy-volunteer levels and lipoprotein(a) reduced 24%, comparable to PCSK9 inhibitors.
The drug was well tolerated with no serious adverse events and TEAE rates similar to placebo (33% vs 30%).
Three Phase 2 studies are planned: GFORCE-2 in coronary artery disease (H1 2027), GEMINI-1 in gout (Q4 2026/Q1 2027, initial data H2 2027), and GALAXY-1 in hidradenitis suppurativa (H1 2027).
• 1mo ago AI analysis › Press Release
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
Monte Rosa Therapeutics will host a live webcast on Thursday, October 1 at 8:00 a.m. ET to review results from the GFORCE-1 Phase 1 study of MRT-8102.
MRT-8102 is a NEK7-directed molecular glue degrader being studied in subjects with elevated cardiovascular disease risk, with data spanning multiple dose levels after 4 weeks of treatment.
The release contains no results themselves; the data drop is a potential catalyst but nothing is disclosed yet.
• 1mo ago AI analysis › Press Release ⚠ 3
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Novartis has initiated a Phase 2a/b study of the VAV1-directed molecular glue degrader MRT-6160 (DDY391) in Sjögren's disease, triggering a $50 million milestone payment to Monte Rosa Therapeutics.
The randomized, double-blind, placebo-controlled, multi-center trial will evaluate up to 52 weeks of treatment to support Phase 3 dose selection, and Monte Rosa is eligible for additional Phase 2 study initiation milestones across immune-mediated diseases.
Under the global exclusive license, Novartis funds and conducts Phase 2 development; Monte Rosa is eligible for up to $2.1 billion in development, regulatory, and sales milestones, will co-fund Phase 3, shares 30% of U.S. profit and loss, and earns tiered royalties on ex-U.S. net sales.
Phase 1 data showed sustained, dose-dependent VAV1 degradation of greater than 90% in peripheral blood T cells, with the drug generally well tolerated and no serious adverse effects observed.
• 1mo ago AI analysis › Press Release
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Therapeutics granted inducement equity awards to six newly hired non-executive employees under its 2026 Inducement Plan, consisting of options on 31,145 shares priced at $14.31 and RSUs covering 6,440 shares.
The options vest 25% on the first anniversary of the September 1 grant date with 36 equal monthly installments thereafter; RSUs vest 25% annually over four years, both subject to continued service.
The awards were approved by the independent compensation committee outside stockholder-approved plans in accordance with Nasdaq Listing Rule 5635(c)(4) — a routine hiring-related disclosure with negligible dilution.
• 1mo ago AI analysis › Press Release
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics announced that management will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference.
CEO Markus Warmuth is scheduled to participate in a fireside chat at the Wells Fargo conference on September 10, 2026.
The company will also attend the Morgan Stanley conference on September 14, with webcasts of the presentations available on its website.
• 2mo ago AI analysis › Press Release
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Monte Rosa Therapeutics dosed the first patient in the Phase 2 MODeFIRe-1 study, evaluating MRT-2359 combined with apalutamide for AR mutation-positive metastatic castration-resistant prostate cancer.
The study advancement is supported by prior Phase 1/2 data where all five patients with AR mutations achieved a PSA response and a 100% disease control rate.
The new trial plans to enroll up to 25 patients using a 0.5 mg dose on a 21-days-on, 7-days-off schedule, with updated data from the earlier study expected by year-end.
• 2mo ago AI analysis › Press Release ● Major ⚠ 2
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
Monte Rosa reported Q2 2026 collaboration revenue of $9.0 million, down from $23.2 million in the prior year, with a net loss of $43.4 million compared to a loss of $12.3 million year-over-year. Despite the financial decline, the company maintains a robust balance sheet with $626.0 million in cash and equivalents, which is expected to fund operations into 2029.
On the clinical front, the company announced the activation of multiple Phase 2 trials. Novartis initiated a Phase 2a/b study of MRT-6160 (DDY391) in Sjögren’s disease, and Monte Rosa activated the MODeFIRe-1 study evaluating MRT-2359 in combination with apalutamide for metastatic castration-resistant prostate cancer.
Enrollment for the GFORCE-1 Phase 1 study of MRT-8102 in subjects with elevated cardiovascular disease risk is complete, with a data readout anticipated in the second half of 2026. Additionally, Monte Rosa expects to initiate three Phase 2 studies for MRT-8102 targeting indications such as atherosclerotic risk, gout flares, and hidradenitis suppurativa by mid-2027.
• 2mo ago AI analysis › Press Release
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Therapeutics granted inducement equity awards to three new non-executive employees pursuant to Nasdaq Listing Rule 5635(c)(4).
The awards consist of non-qualified stock options to purchase 18,025 shares at $24.02 per share and restricted stock units for 3,900 shares.
Options vest 25% on the first anniversary and monthly thereafter, while RSUs vest 25% annually over four years, subject to continued service.
• 4mo ago AI analysis › Press Release
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Therapeutics granted inducement equity awards to four newly hired non-executive employees.
The awards consist of 20,050 non-qualified stock options and 4,400 restricted stock units, totaling 24,450 shares.
The options have an exercise price of $19.67, matching the June 1 closing price, and vest over four years. The grants were made under the 2026 Inducement Plan outside of shareholder-approved plans, in compliance with Nasdaq Listing Rule 5635(c)(4).
• 4mo ago AI analysis › Press Release
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com • 5mo ago Press Release
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Monte Rosa reported Q1 financials with a net loss of $44.5 million and collaboration revenue of $4.2 million, while highlighting a strengthened balance sheet of $671.2 million that supports operations into 2029.
Clinical updates included positive interim data for MRT-8102 showing an 85% reduction in CRP levels, with multiple Phase 2 studies planned for H2 2026.
The oncology program MRT-2359 achieved a 67% disease control rate in mCRPC patients, and Novartis is advancing the partnered MRT-6160 program toward Phase 2 studies in immune-mediated diseases.
• 5mo ago AI analysis › Press Release
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Therapeutics granted inducement equity awards to four new non-executive employees as a material incentive for their employment. The awards, approved by the independent compensation committee, consist of options for 38,925 shares and restricted stock units for 8,550 shares.
The stock options carry an exercise price of $18.80 per share, which was the closing price on the May 1, 2026 grant date. Vesting schedules are structured as 25% on the first anniversary followed by monthly increments for options and 25% annually over four years for the RSUs.
• 5mo ago AI analysis › 
